Please ensure Javascript is enabled for purposes of website accessibility

Merck's Top Cancer Therapy Takes Another Big Leap Forward

By Cory Renauer - May 14, 2020 at 1:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Keytruda's path to becoming the world's top-selling drug looks much smoother following its latest clinical trial success.

Breast cancer patients with particularly aggressive tumor profiles were treated to some good news on Thursday. Clinical trial results from Merck (MRK -0.40%) showed that adding Keytruda to standard chemotherapy reduced those patients' risk of disease progression in the first-line treatment setting. 

A win for triple-negative breast cancer patients

Targeted cancer therapies work well for breast cancer patients with tumors that test positive for estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2 (HER2). Unfortunately, around 15% to 20% of all breast cancer patients have tumors that don't express any of those targets -- thus their designation as "triple-negative" breast cancers. Merck's Keynote-355 trial tested Keytruda as a treatment for triple-negative breast cancer (TNBC) patients who have significant amounts of programmed death-ligand 1 (PD-L1) on their tumors, and the results of the study are compelling. 

Doctor showing a cancer patient their chart.

Image source: Getty Images.

Roughly two-fifths of all TNBC patients have PD-L1 positive tumors, and it looks like Keytruda makes it harder for those tumors to shut down the immune system when it attacks them. Patients with PD-L1 combined positive scores above 10 who were treated with a combination of Keytruda and chemotherapy were 35% less likely to die or show signs of disease progression than patients treated with standard chemotherapy on its own. 

Treatment duration

Keytruda is already on pace to generate sales north of $15 billion in 2020; an approval to treat TNBC patients in the first-line setting could lead to several billion dollars in additional annual revenue. Patients generally respond longest to their first line of treatment, and TNBC patients diagnosed early could wind up taking Keytruda plus chemo for a long time. 

During this interim assessment of the Keynote-355 trial, a majority of patients in the Keytruda plus chemo group had been on therapy for 25.9 months; the trial still hasn't run long enough to produce overall survival data.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$89.16 (-0.40%) $0.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.